Results 201 to 210 of about 602,267 (275)
Brigimadlin versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety, and Translational Data from Brightline-1, a Randomized Phase II/III Trial. [PDF]
Schöffski P +21 more
europepmc +1 more source
Mapping the Safety Profile of Histone Deacetylase Inhibitors in Children with Cancer. [PDF]
Cianflone A +8 more
europepmc +1 more source
Structure and Function of Archaeal SRP54 Protein Mutants Associated with Human Severe Congenital Neutropenia. [PDF]
Yang M +6 more
europepmc +1 more source
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley +1 more source
In this analysis of a diverse cohort of 500 patients with previously untreated DLBCL in a real‐world clinical setting, Pola‐R‐CHP demonstrated high response rates at end‐of‐treatment, which were consistent among the overall population, in patients > 80 years and regardless of International Prognostic Index status and cell of origin subtypes.
Takahiro Kumode +21 more
wiley +1 more source
Neutropenic Tonsillar Ulcer as the Initial Presentation of Acute Myeloid Leukemia in a Young Woman: A Case Report. [PDF]
Al Hassani M +4 more
europepmc +1 more source
ABSTRACT Quizartinib is a FMS‐like tyrosine kinase 3 (FLT3) inhibitor indicated for FLT3 internal tandem duplication (FLT3‐ITD)–positive acute myeloid leukemia (AML). We aimed to evaluate quizartinib resistance mechanisms, in addition to efficacy and safety outcomes, in patients with relapsed or refractory FLT3‐ITD–positive AML.
Yuichiro Semba +21 more
wiley +1 more source
Study protocol for a phase I investigator-initiated clinical trial of E7820 in Japanese patients with unresectable solid tumours: CIRCUS trial (NCCH2303). [PDF]
Okada M +8 more
europepmc +1 more source
ABSTRACT Objectives Pediatric acute myeloid leukemia (AML) chemotherapy regimens are frequently burdened by fever episodes, systemic inflammation and bloodstream infections (BSI). Mucosal barrier injury may contribute to these complications, but its role in childhood AML remains uninvestigated.
Carla Warley Kjær +8 more
wiley +1 more source
Oral Manifestations in Children With Neutropenia: A Systematic Review. [PDF]
Kirubakaran E +4 more
europepmc +1 more source

